A £10 million Centre of Excellence in Precision Medicine has been launched by Invest Northern Ireland and Queen’s University Belfast. The Centre of Excellence in Precision Medicine will develop an
Cancer Biology
Intriguing antitumor activity is found in a very promising class of natural compounds: cyclic depsipeptides, which have a challenging structure that makes their investigation difficult. Now, Chinese scientists have established
EGFR is a common genetic target in lung cancer, but not all EGFR mutations are created equal. Patients with a type of EGFR anomaly called an “EGFR exon 20 insertion”
Eli Lilly has signed up CureVac to develop cancer vaccines based on its mRNA technology, in a deal that could potentially be worth more than $2.6 billion to the German
The NIH and 11 leading biopharmaceutical companies have launched the Partnership for Accelerating Cancer Therapies (PACT), totalling $215m as part of the Cancer Moonshot… The National Institutes of Health (NIH)
The European Patent Office has issued a new patent to biotechnology company, CEL-SCI, for its lead investigational immunotherapy, which is undergoing a Phase III clinical trial for head and neck
A retrospective cohort study, published in the British Medical Journal, has found no conclusive evidence that most oncology treatments approved for use by the European Medicines Agency (EMA) offered survival
Scientists have had positive results from a laboratory-based study using a well-known alcohol aversion drug disulfiram, to combat chemotherapy resistance in the most common type of lung cancer, non-small cell
The cancer immunotherapy pipeline, displays a high level of first-in-class innovation with novel developments focusing heavily on producing the next big immune checkpoint inhibitor, according to GBI Research. GBI Research’s
The UK National Institute for Health and Care Excellence (NICE) has granted approval for Roche’s breast cancer drug Kadcyla for routine use within the NHS region. NICE has recommended Kadcyla
World Cancer Research Fund International has released a new report that demonstrates an increased risk of breast cancer is associated with even moderate alcohol consumption. In the report, a research
Clinigen Group’s Idis Managed Access division and Tesaro have partnered to launch a Managed Access Program (also known as an Early Access Program) in Europe for niraparib, the investigational
Pfizer has announced it will provide its breast cancer drug, palbociclib — which has been provisionally rejected by NICE for routine use as a result of cost — to the
Targovax has recruited its first patient in a Phase Ib trial for its new cancer vaccine TG02 targeting mutations of the RAS gene. Mutations of the RAS gene disrupt normal cell
BTG, a global specialist healthcare company, has received Class III CE Mark certification for DC Bead LUMI, the first commercially available radiopaque drug-eluting bead (DEB) in the EU which can
The European Commission has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC). The
Scientists at EPFL and NTU have discovered that combining an anticancer drug with an antirheumatic produces improved effects against tumors. The discovery opens a new path for drug-drug synergy. One
Apeiron Biologics has announced that the EMA’s CHMP has recommended the approval of APN311 for immunotherapy of high risk neuroblastoma. Apeiron Biologics is a Vienna-based biotech company developing immunological approaches
Novartis has received FDA approval for Kisqali, a first-line treatment for breast cancer originally developed by the British biotech Astex Pharmaceuticals. The oncology company Astex Pharmaceuticals, located in Cambridge’s biotech hub, entered
An epidemiological study published in Frontiers in Oncology suggests that a diet high in carotenoids and vitamin C may protect against lung cancer. The study authors found that vitamin C
The National Institute for Health and Care Excellence (NICE) is half way through a review of drugs approved and still available only through the old Cancer Drugs Fund (CDF). In
Actelion has received approval from the European Commission for Ledaga, a treatment to prevent the progression of a rare form of skin cancer. After being acquired by Johnson & Johnson
A new method to help diagnose oesophageal cancer is being researched by engineers and physicians at the Institute of Biological
Mundipharma is gearing up to launch biosimilar Truxima in seven European markets for the treatment of certain cancers and inflammatory
Roche’s oral ALK inhibitor, Alecensa, has been conditionally approved in the European Union as a monotherapy for anaplastic lymphoma kinase-positive
Scientists at Emory University’s Winship Cancer Institute are on a mission to unlock the mysteries of lung cancer cells that
By hijacking a cancer cell’s own metabolism, researchers have found a way to tag and target elusive cancers with small-molecule
One of Europe’s largest collaborative academic-industry research projects, designed to develop and assess novel approaches for identification of new markers
As recently published in the International Journal of Cancer, researchers from Breast-Predict, may have found a new drug for the
Advertisements
